Navigation Links
Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
Date:2/26/2008

hase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory diseases. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including the expected properties and benefits of RDEA806, RDEA119 and its other compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... (PRWEB) March 29, 2015 A two-day ... United States and plenary talks by four leading photonics ... Optics + Optoelectronics next month in Prague, Czech ... in 17 conferences alongside a two-day exhibition. Sponsored by ... , the event will run 13-16 April in the ...
(Date:3/30/2015)... 2015 Richmond Pharmacology nimmt ... Pharmacology ist das erste Zentrum weltweit, das in ... Hospital in London in ... Studienversuche an einem Patienten begonnen hat. Das Therapeutikum ... entwickelt (ATTR), einer seltenen Herz- und Nervenkrankheit. ...
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
(Date:3/27/2015)... Earlier this year, the Capillus272Pro™ received ... in adult men and women with androgenic alopecia (AGA) ... of IIa-V and Fitzpatrick Classification of Skin phototypes I-IV. ... over-promise and under-deliver, FDA Clearance underscores the safety and ... more than 80 million men and women who suffer ...
Breaking Biology Technology:Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2
... 3 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... development and commercialization of novel drugs in the,therapeutic ... it will present and participate in a panel ... Annual JPMorgan Healthcare Conference on January 9,2008., ...
... CEO to Provide Update on the Clinical and Commercial ... Axxent(R) ... Xoft, Inc., developer of the,Axxent(R) Electronic Brachytherapy System, a ... isotope-free,radiation therapy directly to cancer sites, today announced that ...
... to Manufacture; Genzyme will Continue to Market and ... ... and CAMBRIDGE, Mass., Jan. 3 ,BioMarin Pharmaceutical Inc. (Nasdaq and ... a restructuring of their joint venture,regarding Aldurazyme(R) (laronidase). Under the ...
Cached Biology Technology:Advanced Life Sciences to Present at Biodefense Session of 26th Annual JPMorgan Healthcare Conference 2Xoft to Present at the 26th Annual JPMorgan Healthcare Conference 2BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 2BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 3BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 4BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 5
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces its ... of the products featured in 2015 "I Want That" ... PM EST on the DIY Network.   ... Vegas , site of the 2015 International CES ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... from the University of Maryland and Beijing Normal University ... climate change internationally. When fully developed, the project ... for example, predict crop failure and changes in commodity ... At the University of Maryland today, officials from ...
... AMES, Iowa Genetic mutations to cellulose in plants could ... a research team that included two Iowa State University chemists. ... early edition of the Proceedings of the National Academy ... chemistry and an associate of the U.S. Department of Energy,s ...
... child,s cognitive development is not generally impacted by how ... according to a study from Nationwide Children,s Hospital. ... for the widest range of confounding factors when directly ... cognition. Insufficient or excessive weight gain in ...
Cached Biology News:UMD and Chinese partner to track and predict world climate change 2Iowa State, Ames Lab chemists aid study of mutated plants that may be better for biofuels 2Gestational weight gain generally does not influence child cognitive development 2
... The CHEMICON MDR1 Shift Assay provides a convenient ... occur upon transport of MDR1 substrates. Thus, the ... to which small molecules act as transport substrates ... in the presence of MDR1 substrates, the MDR1 ...
... The wide and long electrophoresis ... Polaroid gel documentation systems. Placed ... the camera in place and ... allows photography on the lab ...
... derived from Paraffin embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 5 ... are large (3-5 mm in diameter) in ...
... are derived from frozen embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... are large (3-5mm in diameter) in comparison ...
Biology Products: